We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

179 hedge funds and large institutions have $1.21B invested in Sarepta Therapeutics in 2017 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% more call options, than puts

Call options by funds: $108M | Put options by funds: $54.9M

45% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 44

39% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 28

11% more capital invested

Capital invested by funds: $1.08B → $1.21B (+$123M)

2.09% more ownership

Funds ownership: 72.29% → 74.38% (+2.1%)

1% more funds holding

Funds holding: 177 → 179 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
179
Holders Change
+2
Holders Change %
+1.13%
% of All Funds
4.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
39
Increased
64
Reduced
44
Closed
28
Calls
$108M
Puts
$54.9M
Net Calls
+$53.5M
Net Calls Change
+$36.4M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$160M
2
HM
HealthCor Management
New York
+$48M
3
CCM
Camber Capital Management
Massachusetts
+$41.8M
4
O
OrbiMed
New York
+$32.6M
5
PC
PointState Capital
New York
+$19.8M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$62.4M
2
PA
Perceptive Advisors
New York
-$30.9M
3
ACA
Avoro Capital Advisors
New York
-$27.7M
4
JG
Jefferies Group
New York
-$26M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
MWM
176
MinichMacGregor Wealth Management
New York
$1K – – –
RAM
177
Riggs Asset Management
Pennsylvania
$1K – – –
PA
178
Parallel Advisors
California
$1K +$898 +29 New
SM
179
Sabby Management
Florida
– -$62.4M -2,014,787 Closed
ACA
180
Avoro Capital Advisors
New York
– -$27.7M -1,010,300 Closed
JG
181
Jefferies Group
New York
– -$26M -839,342 Closed
Two Sigma Investments
182
Two Sigma Investments
New York
– -$7.22M -263,229 Closed
QIM
183
Quantitative Investment Management
Virginia
– -$5.41M -197,400 Closed
Voloridge Investment Management
184
Voloridge Investment Management
Florida
– -$4.38M -159,580 Closed
O
185
OppenheimerFunds
New York
– -$2.86M -104,350 Closed
HCMT
186
Highland Capital Management (Texas)
Texas
– -$2.35M -85,600 Closed
Nomura Holdings
187
Nomura Holdings
Japan
– -$1.24M -44,720 Closed
HT
188
HAP Trading
New York
– -$1M -36,556 Closed
SIM
189
Spark Investment Management
New York
– -$987K -36,000 Closed
HCM
190
Highbridge Capital Management
New York
– -$845K -30,809 Closed
Jane Street
191
Jane Street
New York
– -$746K -24,120 Closed
IBT
192
International Biotechnology Trust
United Kingdom
– -$576K -21,000 Closed
NI
193
Numeric Investors
Massachusetts
– -$557K -20,300 Closed
Janney Montgomery Scott
194
Janney Montgomery Scott
Pennsylvania
– -$446K -16,246 Closed
CAM
195
ClariVest Asset Management
California
– -$382K -13,931 Closed
EIM
196
Essex Investment Management
Massachusetts
– -$303K -11,063 Closed
LCM
197
Laurion Capital Management
New York
– -$302K -11,000 Closed
NIT
198
NumerixS Investment Technologies
British Columbia, Canada
– -$255K -9,293 Closed
SCM
199
Sterling Capital Management
North Carolina
– -$252K -9,205 Closed
HSBC Holdings
200
HSBC Holdings
United Kingdom
– -$240K -8,750 Closed
5 6 7
8
9

SRPT Hedge Fund Activity: Q1 2017 in Review

179 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2017, worth a combined $1.21B — up 11% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SRPT positions and 28 closed out — a net gain of 11 holders — while 64 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $160M. The largest seller was Sabby Management, exiting entirely with an estimated $62.4M sold.

  • 179 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2017, up from 177 in Q4 2016.
  • Funds reported $1.21B of Sarepta Therapeutics stock for Q1 2017, up 11% quarter-over-quarter.
  • 39 funds opened new Sarepta Therapeutics positions in Q1 2017 and 28 closed out, a net change of +11 holders.
  • The largest Sarepta Therapeutics buyer in Q1 2017 was BlackRock, an estimated $160M added.
  • The largest Sarepta Therapeutics seller in Q1 2017 was Sabby Management, an estimated $62.4M sold.

Based on aggregated 13F filings for Q1 2017.